Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas. Results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma
• Subcutaneous Panniculitis-like T-cell Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pralatrexate (pralatrexate)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-27